Page last updated: 2024-08-16

temozolomide and gpi 15427

temozolomide has been researched along with gpi 15427 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alemu, C; Calvin, D; Graziani, G; Hoover, R; Lapidus, R; Leonetti, C; Morgan, L; Scarsella, M; Tang, Z; Tentori, L; Vergati, M; Woznizk, K; Xu, W; Zhang, J	1
Cuzzocrea, S; Dorio, AS; Forini, O; Graziani, G; Lapidus, R; Leonetti, C; Mazzon, E; Muzi, A; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J	1

Other Studies

2 other study(ies) available for temozolomide and gpi 15427

Article	Year
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. International journal of oncology, 2005, Volume: 26, Issue:2 Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Blood-Brain Barrier; Brain; Cell Line, Tumor; Central Nervous System Neoplasms; Chromatography, Liquid; Dacarbazine; Disease Models, Animal; Enzyme Inhibitors; Flow Cytometry; G2 Phase; Humans; Inhibitory Concentration 50; Kinetics; Mass Spectrometry; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Organic Chemicals; Poly(ADP-ribose) Polymerases; Rats; Rats, Sprague-Dawley; Temozolomide; Time Factors	2005
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2006, Volume: 20, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Colonic Neoplasms; Colony-Forming Units Assay; Dacarbazine; Diarrhea; Drug Synergism; Enzyme Inhibitors; Intestinal Diseases; Irinotecan; Organic Chemicals; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Topoisomerase I Inhibitors; Tumor Burden	2006

Article

Year

Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.

International journal of oncology, 2005, Volume: 26, Issue:2

Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Blood-Brain Barrier; Brain; Cell Line, Tumor; Central Nervous System Neoplasms; Chromatography, Liquid; Dacarbazine; Disease Models, Animal; Enzyme Inhibitors; Flow Cytometry; G2 Phase; Humans; Inhibitory Concentration 50; Kinetics; Mass Spectrometry; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Organic Chemicals; Poly(ADP-ribose) Polymerases; Rats; Rats, Sprague-Dawley; Temozolomide; Time Factors

2005

Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2006, Volume: 20, Issue:10

Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Colonic Neoplasms; Colony-Forming Units Assay; Dacarbazine; Diarrhea; Drug Synergism; Enzyme Inhibitors; Intestinal Diseases; Irinotecan; Organic Chemicals; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Topoisomerase I Inhibitors; Tumor Burden

2006